COVID-19 vaccine: Bangladesh's Beximco Pharma ties up with India's Serum Institute

Beximco Pharmaceuticals, one of the leading drugmakers of Bangladesh, announced it will invest with the Serum Institute of India (SII) to ensure Bangladesh receives COVID-19 vaccine on a priority basis, once approved by the regulator

Aug 29, 2020
Image
a

Beximco Pharmaceuticals, one of the leading drugmakers of Bangladesh, announced it will invest with the Serum Institute of India (SII) to ensure Bangladesh receives COVID-19 vaccine on a priority basis, once approved by the regulator.

The announcement came more than a week after Indian Foreign Secretary Harsh Vardhan Shringla's visit to Dhaka and a day after the Bangladesh government announced approval of the stage three trial of a vaccine of Chinese company -- Sinovac Research and Development Co Ltd.

During Shringla's visit, Dhaka had sought to collaborate with Indian vaccine developers for trial in Bangladesh. The secretary did not speak of any collaboration for the trial, but said Bangladesh would be a priority country in terms of getting COVID-19 vaccines once developed and approved.


https://www.thedailystar.net/frontpage/news/beximco-pharma-ties-indian-firm-1952677
 

downloadingmymind.com

SPS-NBN

News Behind the News Special Studies

Tweets about SAMonitor
SAM Facebook

Newsletter Subscription

The subscriber's email address.
Stay informed - subscribe to our newsletter.